How Cloud to Edge Technology Helps Handle the Immense Amount of Data Generated By Practitioners

 

Healthcare organizations generate massive amounts of data, so much so that the challenge becomes how and where to move it and store it.

Health and Life Science at the Edge host, Gabrielle Bejarano, spoke with Zettar’s Chin Fang and Intel’s Michael McManus for a peek inside the technology solutions Zettar and Intel are partnering on to advance the challenge of data movement, processing, and storage for healthcare organizations.

Genomics files are a perfect example of the type of sizable data files that life science companies are creating. “When you go to genomics, for example, genomics files, a whole genome for a single person is about 350 gigabytes,” McManus says. “So, if you’re sequencing many people, you multiply however many people, you’re sequencing times 350 gigabytes for your storage planning purpose.” And he says cryoelectronic microscopy data sets are multiple terabytes in sizes. The data is broken into single gigabyte movies, and the average microscope can create thousands of those an hour. And then, the data requires analysis.

Chin adds there are some institutions Zettar works with whose processes generate files as big as four terabytes with rates of one terabyte per second that requires aggressive data reduction to reduce that to the gross rate of 800 Gbps, or 100 gigabytes per second.

These huge datasets cause a myriad of problems for technicians, scientists, and IT staff, including wasted time, frustration, and a loss of productivity.

Standard data-moving practices can’t handle these complex situations, so Zettar’s approach utilizes an efficient unified data-mover model. “With Intel’s help, we developed this real-time capability, so now we make the real-time data movement readily available to anyone who needs it, and then this will have great benefits to accelerate the healthcare and life sciences research efforts going forward,” Chin says.

Learn more about Health and Life Science data movement solutions by connecting with Chin Fang and Michael McManus on LinkedIn or visit Intel Health and Life Sciences.  

Subscribe to this channel on Apple PodcastsSpotify, and Google Podcasts to hear more from the Intel Health and Life Sciences at the Edge.

Follow us on social media for the latest updates in B2B!

Image

Latest

AI in marketing
From Queries to Conversations with AI in Marketing Analytics
April 21, 2025

In this episode of the SparkCast, Aby Varma—founder of Spark Novus, a firm that helps marketing leaders adopt AI responsibly and strategically—sits down with Daniel Kravtsov, CEO and Co-Founder of Improvado. Daniel shares his unique journey from Russia to founding a cutting-edge martech company in the Bay Area. Together, they explore how AI agents…

Read More
ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More